Our ecosystem and network
The Institute for Translational Medicine and Liver Disease is a pioneer in the fundamental and translational research of liver disease. The institute’s laboratories are located within the University of Strasbourg Campus of Medicine. By federating several French organisms and institutions, this competitiveness cluster develops and promotes health research of excellence through innovation. The unit is a powerhouse of scientific excellence, training, and innovation. Due to its strategic location within the fantastic Strasbourg ecosystem, a cornerstone of the unit’s success is its strong integration within the Strasbourg competitiveness cluster. This unique pole of excellence includes leading institutions such as Strasbourg University Hospitals, IHU Strasbourg, the Center for Clinical Investigations (CIC), the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) the Institut de Biologie Moléculaire et Cellulaire (IBMC), the Centre de Recherche en Biomédecine de Strasbourg (CRBS), and the Institut de Chimie (UMR_S7177).
The unit is actively participating and shaping the initiative of excellence of the University of Strasbourg as a laureate of a Laboratory of Excellence (LabEx) and several Initiative d’Excellence (IdEx) awards of the University Strasbourg. Since 2021, the ITM is part of the research cluster Institut Thématique Interdisciplinaire (ITI) IMCBio+, and since 2024, we are partner of the ENACT Cluster, dedicated to Artificial Intelligence.
Collaborations
Moreover, ITM has ongoing collaborations and networks with leading international experts in the field, including partners for systems biology and computational analyses with the Broad Institute of MIT, and Massachusetts General Hospital, Harvard Medical School, UTSW Dallas, as well as liver disease and cancer specialists at the and Tisch Cancer Center, Mount Sinai Hospital, New York, the German Cancer Research Center, Heidelberg, the M3 Institute, University of Tübingen, AP-HP and Inserm Paris, experts in HBV and HDV virology with CIRI Lyon, the CRLC Lyon, Hanover Medical School and Hamburg University Hospitals and a HCV/SARS-CoV2 vaccine collaboration with Stanford University Medical School. Joint research on HBV, HCV, and SARS-CoV2 has been carried out together with Oxford University.
Currently ongoing programs also include AP-HP Paris, University Hospital Basel, Geneva University Hospitals and University of Geneva, Freiburg University Hospitals, Hiroshima University Hospitals, University of Leuven, University of Nebraska Medical Center, and University of Toronto.
